MHRA refreshes exceptional use device lists as authorisations turn over
The MHRA has updated its medical devices given exceptional use authorisations register again, extending some exemptions, closing others, and revising the status of products that have moved back into conformity. The page functions as a living regulatory record rather than a single static notice, and the latest refresh shows how quickly device access can shift when a product is needed before the full conformity pathway is complete or when a temporary derogation has run its course.
One sentence captures the regulatory reality: exceptional use is temporary by design.
The most recent update, dated 27 October 2026, states that both the active list and the list of devices no longer covered by exceptional use authorisation were updated. That pattern has repeated throughout the record, with extensions issued for some products and closure notices applied to others once expiry dates arrived or conformity was restored. The cadence matters for hospitals, procedural teams, and procurement staff because device availability can change while a clinical service is midstream, especially in specialties dependent on narrow product specifications, sterile consumables, or highly specialized procedural kits.
A rolling register for devices that need temporary regulatory flexibility
The page covers manufacturers and devices granted an exemption by the MHRA, while also cataloguing manufacturers whose exemption has expired or been cancelled. In practical terms, the register gives clinicians and supply-chain teams a way to identify products that may remain in use under a specific authorisation window even though normal market conformity rules have not fully resolved the issue. That is especially relevant in settings where replacement is not immediate, where a device is tied to an ongoing procedure program, or where a specific component cannot simply be substituted without affecting the workflow.
Several late-stage updates illustrate the kind of turnover these lists absorb. Some entries receive extension dates, including devices associated with accessory products, blood collection systems, surgical hardware, perfusion systems, and software-linked diagnostic tools. Others move from the open list to the closed list after the derogation period ends or after return to conformity within that period. The latest revisions also show removals from the closed list in certain instances, indicating that the register is not a simple archive but an active administrative tool that can be revised when status changes.
Why temporary authorisation matters at the bedside
Exceptional use authorisation exists to prevent a regulatory gap from becoming an immediate clinical gap. When a device is central to treatment delivery — for example, perfusion equipment, blood management components, neurosurgical accessories, anesthesia kits, or specialized laboratory systems — interruption can ripple directly into patient scheduling, operating room throughput, and diagnostic turnaround. The biologic principle is simple even when the paperwork is not: if the right device is unavailable, the clinical pathway can stall.
A short extension can preserve continuity for a service line that has already trained staff on a specific platform, validated workflows, or integrated the device into a tightly controlled protocol. In a surgical environment, even a small hardware change may require revalidation of technique, new staff training, and fresh safety checks. In laboratory medicine, a software or instrumentation change can affect specimen handling, assay compatibility, and result flow. The authorisation list therefore carries consequences well beyond the regulatory office; it shapes whether a clinical unit can keep functioning on the terms it has already built around a given device.
The device mix shows how broad the regulatory net has become
The current and historical updates encompass a wide spread of device classes. Blood collection systems, warming systems, perfusion products, stereotactic hardware, pain management kits, catheter systems, hearing test systems, and laboratory analysis platforms all appear across the update history. Such breadth reflects the fact that exceptional use is not reserved for one specialty or one type of failure. It can arise in almost any area where a device underpins care delivery and where a temporary regulatory path is needed to keep patients moving through treatment.
Several entries show how authorisations can be extended multiple times before finally expiring or being withdrawn. Others demonstrate how a product may be added to the open list, modified, or transferred to the closed list depending on status. For clinicians, the operational message is straightforward: device status is not frozen, and checks against the active register need to be part of routine procurement and procedural planning.
This list also offers a quiet reminder about device governance. Regulatory flexibility does not remove the obligation to monitor safety, traceability, and conformity. It only creates a managed bridge while those issues are being resolved or while supply continuity is being maintained under controlled conditions. In that sense, the exceptional use pathway is less about lowering standards than about preventing abrupt disruption when a standard pathway is temporarily incomplete.
What the evolving register signals for regulated care
The sustained flow of updates across 2024, 2025, and 2026 shows that exceptional use authorisations are being used repeatedly rather than rarely. Some entries persist for months; others are closed once the derogation window ends. The list now spans a large number of manufacturers and device models, and the recurring extensions suggest that regulatory management of devices is often iterative, not binary.
For patient care teams, the practical takeaway is immediate and concrete: the active and closed lists should be checked before relying on a device whose regulatory status may be time-limited. A device can remain available in one month and move off the open list in the next. Procurement delays, delayed replacements, or missed expiry dates can affect whether a unit can continue a procedure without interruption.
The current page does not provide outcome data, adverse event rates, or patient-level performance metrics. It does, however, define the regulatory envelope within which care teams operate. That envelope changes repeatedly, and the latest update confirms that the MHRA is still revising both the live authorisation list and the archive of devices that are no longer covered by exceptional use. The unresolved issue is not whether these devices matter — it is how often services must adapt around their changing status while maintaining uninterrupted care.